Tenaya Therapeutics, Inc. Operating Lease, Payments
Tenaya Therapeutics, Inc. (TNYA) reported Operating Lease, Payments of $1.91 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-08-05
- Tenaya Therapeutics, Inc. operating lease, payments for the quarter ending 2026-06-30 was $960.00K, a 1.84% decline year-over-year.
- Tenaya Therapeutics, Inc. operating lease, payments for the quarter ending 2026-03-31 was $947.00K, a 4.25% decline year-over-year.
- Tenaya Therapeutics, Inc. operating lease, payments for the quarter ending 2025-12-31 was $947.00K, a 23.51% decline year-over-year.
- Tenaya Therapeutics, Inc. operating lease, payments for the quarter ending 2025-09-30 was $947.00K, a 30.47% decline year-over-year.
- Tenaya Therapeutics, Inc. operating lease, payments for fiscal 2025 was $3.86M, a 26.83% decline from fiscal 2024.
- Tenaya Therapeutics, Inc. operating lease, payments for fiscal 2024 was $5.28M, a 1.31% decline from fiscal 2023.
- Tenaya Therapeutics, Inc. operating lease, payments for fiscal 2023 was $5.35M.
- Tenaya Therapeutics, Inc. operating lease, payments for fiscal 2021 was $6.11M.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $960.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $1.91M 10-Q · filed 2026-08-05 | $2.85M derived: sum of 3 quarters · filed 2026-08-05 | $3.80M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $947.00K 10-Q · filed 2026-05-06 | $1.89M derived: sum of 2 quarters · filed 2026-05-06 | $2.84M derived: sum of 3 quarters · filed 2026-05-06 | $3.82M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $947.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $1.89M derived: sum of 2 quarters · filed 2026-03-11 | $2.87M derived: sum of 3 quarters · filed 2026-08-05 | $3.86M 10-K · filed 2026-03-11 |
| 2025-09-30 | $947.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $1.93M derived: sum of 2 quarters · filed 2026-08-05 | $2.91M 10-Q · filed 2025-11-10 | $4.15M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $978.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $1.97M 10-Q · filed 2026-08-05 | $3.21M derived: sum of 3 quarters · filed 2026-08-05 | $4.57M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $989.00K 10-Q · filed 2026-05-06 | $2.23M derived: sum of 2 quarters · filed 2026-05-06 | $3.59M derived: sum of 3 quarters · filed 2026-05-06 | $4.93M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $1.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $2.60M derived: sum of 2 quarters · filed 2026-03-11 | $3.94M derived: sum of 3 quarters · filed 2026-03-11 | $5.28M 10-K · filed 2026-03-11 |
| 2024-09-30 | $1.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $2.71M derived: sum of 2 quarters · filed 2025-11-10 | $4.04M 10-Q · filed 2025-11-10 | $5.39M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $1.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $2.68M 10-Q · filed 2025-08-06 | $4.02M derived: sum of 3 quarters · filed 2025-08-06 | $5.38M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $1.33M 10-Q · filed 2025-05-07 | $2.68M derived: sum of 2 quarters · filed 2025-05-07 | $4.03M derived: sum of 3 quarters · filed 2025-05-07 | $5.36M derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | $1.35M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $2.70M derived: sum of 2 quarters · filed 2025-03-10 | $4.03M derived: sum of 3 quarters · filed 2025-03-10 | $5.35M 10-K · filed 2025-03-10 |
| 2023-09-30 | $1.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $2.69M derived: sum of 2 quarters · filed 2024-11-06 | $4.00M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $1.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $2.65M 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $1.31M 10-Q · filed 2024-05-14 | |||
| 2022-03-31 | $1.37M 10-Q · filed 2022-05-11 | $3.05M derived: sum of 2 quarters · filed 2022-05-11 | $4.65M derived: sum of 3 quarters · filed 2022-05-11 | $6.09M derived: sum of 4 quarters · filed 2022-05-11 |
| 2021-12-31 | $1.69M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-23 | $3.28M derived: sum of 2 quarters · filed 2022-03-23 | $4.72M derived: sum of 3 quarters · filed 2022-03-23 | $6.11M 10-K · filed 2022-03-23 |
| 2021-09-30 | $1.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $3.03M derived: sum of 2 quarters · filed 2021-11-10 | $4.42M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $1.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-09-08 | $2.83M 10-Q · filed 2021-09-08 | ||
| 2021-03-31 | $1.39M 10-Q · filed 2022-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |